Department of Surgery, Dankook University Hospital College of Medicine, 201 Manghyangro, Dongnam-Gu, Cheonan, 31116, Republic of Korea.
Int J Colorectal Dis. 2023 Feb 16;38(1):44. doi: 10.1007/s00384-023-04340-w.
This study aimed to examine the 7-year follow-up results of cytoreductive surgery (CRS) and intraperitoneal chemotherapy (IPC) for peritoneal metastasis (PM) of colorectal cancer.
We performed 54 cases of CRS and IPC in 53 patients with PM of colorectal cancer from December 2011 to December 2013. We prospectively collected data and analyzed peritoneal carcinomatosis grade, completeness of cytoreduction, and long-term follow-up (median, 10 [range, 2-92] months) results.
The mean peritoneal cancer index was 15 (1 ~ 35), and complete cytoreduction was possible in 35 (64.8%) patients. Excluding the four patients who died, 11 (22.4%) out of the 49 patients were alive at the time of the last follow-up, and the overall median survival period was 10.3 months. The overall 2- and 5-year survival rates were 31% and 17%, respectively. Patients with complete cytoreduction had a median survival period of 22.6 months, which was significantly longer than that for patients without complete cytoreduction (3.5 months) (P < 0.001). The 5-year survival rate for patients with complete cytoreduction was 24%, and four patients were still alive without disease.
CRS and IPC show a 5-year survival rate of 17% in patients with PM of colorectal cancer. A possibility of long-term survival is observed in a selected group. Multidisciplinary team evaluation for careful patient selection and CRS training program to achieve complete cytoreduction are significantly important factors in improving survival rate.
本研究旨在探讨结直肠癌细胞减灭术(CRS)联合腹腔热灌注化疗(IPC)治疗结直肠腹膜转移(PM)的 7 年随访结果。
我们对 2011 年 12 月至 2013 年 12 月期间收治的 53 例结直肠 PM 患者实施了 54 例 CRS 和 IPC。我们前瞻性地收集了数据,并对腹膜癌细胞转移分级、细胞减灭术的完整性以及长期随访(中位数为 10 [范围为 2~92] 个月)结果进行了分析。
腹膜癌指数平均为 15(1~35),35 例(64.8%)患者可达到完全细胞减灭术。在排除 4 例死亡患者后,49 例患者中有 11 例(22.4%)在最后一次随访时仍存活,总中位生存时间为 10.3 个月。总的 2 年和 5 年生存率分别为 31%和 17%。完全细胞减灭术患者的中位生存时间为 22.6 个月,明显长于未达到完全细胞减灭术患者的 3.5 个月(P<0.001)。完全细胞减灭术患者的 5 年生存率为 24%,有 4 例患者仍无病生存。
CRS 和 IPC 治疗结直肠 PM 患者的 5 年生存率为 17%。在选择的患者中,观察到长期生存的可能性。多学科团队评估、仔细的患者选择以及实现完全细胞减灭术的 CRS 培训计划是提高生存率的重要因素。